639784-17-1Relevant articles and documents
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δAgonist for the Treatment of Primary Biliary Cirrhosis
Jiang, Zhigan,Liu, Xing,Yuan, Zhiliang,He, Haiying,Wang, Jing,Zhang, Xiao,Gong, Zhen,Hou, Lijuan,Shen, Liang,Guo, Fengxun,Zhang, Jiliang,Wang, Jianhua,Xu, Deming,Liu, Zhuowei,Li, Haijun,Chen, Xiaoxin,Long, Chaofeng,Li, Jian,Chen, Shuhui
, p. 1068 - 1073 (2019)
A novel peroxisome proliferator-activated receptor (PPAR) α/δdual agonist 5c was developed with an EC50 of 8 nM for PPARα, 5 nM for PPARδ, and >300-fold selectivity against PPARγ(EC50 = 2939 nM), respectively. Further ADME and pharma
AMORPHOUS PYRROLIDINE DERIVATIVE AS PPAR AGONIST AND PREPARATION METHOD THEREOF
-
Paragraph 0048-0051, (2020/11/30)
The present invention relates to an amorphous pyrrolidine derivative as a PPAR agonist and a preparation method thereof.
SOLID FORMS OF ELAFIBRANOR AND PROCESSES THEREOF
-
Page/Page column 13, (2019/10/23)
The present invention relates to solid forms of Elafibranor, processes for preparation thereof, pharmaceutical salts of Elafibranor, their crystalline and amorphous forms and processes for preparation thereof.